Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses
Neuro-Oncology · 12.01.2025 · 27 (1) · 89-105
DOI: 10.1093/neuonc/noae214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 19.11.2024. Verfasst von Calixto-Hope G Lucas und 28 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Brain Tumor Center, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Isocitrate Dehydrogenase, Mutation. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, Sandler Foundation.
Abstract (Originalsprache)
Background
Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous response to the current standard-of-care treatment regimen consisting of maximal safe resection, adjuvant radiation, and chemotherapy with temozolomide remain unknown.
Methods
Comprehensive histopathologic, genomic, and epigenomic evaluation of paired initial and recurrent glioblastoma specimens from 106 patients was performed to investigate the molecular evolution and cellular phenotypes underlying differential treatment responses.
Results
While TERT promoter mutation and CDKN2A homozygous deletion were early events during gliomagenesis shared by initial and recurrent tumors, most other recurrent genetic alterations (eg, EGFR, PTEN, and NF1) were commonly private to initial or recurrent tumors indicating acquisition later during clonal evolution. Furthermore, glioblastomas exhibited heterogeneous epigenomic evolution with subsets becoming more globally hypermethylated, hypomethylated, or remaining stable. Glioblastoma that underwent sarcomatous transformation had shorter interval to recurrence and were significantly enriched in NF1, TP53, and RB1 alterations and the mesenchymal epigenetic class. Patients who developed somatic hypermutation following temozolomide treatment had significantly longer interval to disease recurrence and prolonged overall survival, and increased methylation at 4 specific CpG sites in the promoter region of MGMT was significantly associated with this development of hypermutation. Finally, an epigenomic evolution signature incorporating change in DNA methylation levels across 347 critical CpG sites was developed that significantly correlated with clinical outcomes.
Conclusions
Glioblastoma undergoes heterogeneous genetic, epigenetic, and cellular evolution that underlies prognostically different treatment responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCSF Brain Tumor Center, University of California, San Francisco, California, USA.
- Department of Pathology, University of California, San Francisco, California, USA.
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Neurological Surgery, University of California, San Francisco, California, USA.
- Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.
- Department of Neurology, University of California, San Francisco, California, USA.
ORCID-Profile: Calixto-Hope G Lucas, Nancy Ann Oberheim Bush, John de Groot, Shawn L Hervey-Jumper, David R Raleigh, Aaron A Diaz, Jennifer L Clarke, Susan M Chang, David A Solomon
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- Sandler Foundation
- NIH HHS
- NLM NIH HHS
- Gilbert Family Foundation
- Panattoni Family Foundation
- National Cancer Institute
Zitieren
APA
Lucas, C. G., Al-Adli, N. N., Young, J. S., Gupta, R., Morshed, R. A., Wu, J., Ravindranathan, A., Shai, A., Oberheim Bush, N. A., Taylor, J. W., de Groot, J., Villanueva-Meyer, J. E., Pekmezci, M., Perry, A., Bollen, A. W., Theodosopoulos, P. V., Aghi, M. K., Chang, E. F., Hervey-Jumper, S. L., …, & Solomon, D. A. (2025). Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro-Oncology, 27(1), 89-105. https://doi.org/10.1093/neuonc/noae214
Vancouver
Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, et al. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro-Oncology. 2025;27(1):89-105. doi:10.1093/neuonc/noae214
BibTeX
@article{Lucas2025,
author = {Lucas, Calixto-Hope G and Al-Adli, Nadeem N and Young, Jacob S and Gupta, Rohit and Morshed, Ramin A and Wu, Jasper and Ravindranathan, Ajay and Shai, Anny and Oberheim Bush, Nancy Ann and Taylor, Jennie W and de Groot, John and Villanueva-Meyer, Javier E and Pekmezci, Melike and Perry, Arie and Bollen, Andrew W and Theodosopoulos, Philip V and Aghi, Manish K and Chang, Edward F and Hervey-Jumper, Shawn L and Raleigh, David R and Molinaro, Annette M and Costello, Joseph F and Diaz, Aaron A and Clarke, Jennifer L and Butowski, Nicholas A and Phillips, Joanna J and Chang, Susan M and Berger, Mitchel S and Solomon, David A},
title = {Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {1},
pages = {89--105},
doi = {10.1093/neuonc/noae214}
}
EUVIMED